# CONTENTS

Chapter 1: Introduction and Review of Literature  
1.1 Introduction  
1.2 Lung cancer statistics and epidemiology  
1.3 Risk factor associated with lung cancer  
1.4 Lung cancer histopathology  
1.4.1 Small cell lung cancer  
1.4.2 Large cell carcinoma  
1.4.3 Adenocarcinomas  
1.4.4 Squamous cell carcinoma  
1.4.5 Non small cell lung cancer (NSCLC)  
1.4.5.1 Staging  
1.4.5.2 Screening  
1.4.5.3 Treatment  
1.4.5.4 Surgery  
1.4.5.5 Chemotherapy  
1.4.5.6 Adjuvant chemotherapy  
1.4.5.7 Radiotherapy  
1.4.5.8 Targeted therapy  
1.5 ERBB receptor family of proteins  
1.6 EGFR inhibitors currently in use  
1.6.1 Gefitinib  
1.6.2 Erlotinib  
1.6.2.1 Phase I and II clinical studies of Erlotinib  
1.6.2.2 Phase III clinical studies of Erlotinib  
1.7 Mutations identified in the EGF receptor  
1.7.1 Mutation status in the Asian population  
1.8 High throughput strategies for profiling of cancer  
1.9 Signaling and biomarkers  
1.10 Mass spectrometry and lung cancer  
1.11 Mass spectrometric investigation of phosphorylation kinetics  
1.12 Phosphorylation and the EGF receptor  
1.13 Signaling pathways in adenocarcinoma cells H3255  

Chapter 2: Aims and Objectives  
2.1 Introduction  
2.1 Aim 1  
2.2 Aim 2  
2.3 Aim 3
Chapter 3: Methodology
3.1 Introduction 32
3.2 Cell culture and preparation of lysates 32
3.3 Tryptic digestion of peptides and purification of peptides 33
3.4 Strong cation exchange (SCX) chromatographic fractionation 33
3.5 Titanium dioxide (TIO2) enrichment 34
3.6 Tyrosine phosphopeptide enrichment 34
3.7 LC-MS/MS analysis 35
3.8 Data analysis 35
3.9 Immunodetection assays 36
3.10 IPA analysis to identify canonical pathways 36

Chapter 4: Identification of Signaling Molecules Regulated by the EGFR inhibitor Erlotinib
4.1 Introduction 38
4.2 Results and discussion 39
   4.2.1 Effect of Erlotinib on EGF signaling 41

Chapter 5: Signaling Pathways that are modulated on EGFR Inhibition 45
5.1 Introduction 45
5.2 Results and discussion 46
5.3 ERBB receptor signaling 57
5.7 PI3K/AKT/MTOR signaling pathway 60
5.8 VEGF receptor family 66
5.9 FGF receptor family 67
5.10 Ephrin receptor family 68
5.11 Other classes of molecules modulated on EGF and Erlotinib 70
   5.11.1 Kinases 70
   5.11.2 Phosphatases 77
   5.11.3 Molecules that constitute the autophagy system 78
5.11.4 Transcription/translation related molecules 80
5.11.5 Other molecules of interest 80

CHAPTER 6: Conclusions and Future Perspectives:
6.1 Conclusions 85
6.2 Future perspectives 86

References 88

Appendix 101